Challenges in the management of breast cancer in low and middle income countries

Challenges in the management of breast cancer in low and middle income countries

VJOncology

3 years
804 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Cheng-Har Yip, MB, BS, FRCS of Breast Surgery International, Malaysia discusses the challenges in the management of breast cancer in low and middle income countries at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. Dr Yip explains that the incidence of breast cancer is lower in developing countries but increasing rapidly. Further, women present with late stages of breast cancer; more than 50% of women present with stage 3 and 4. She explains that mortality in low and middle income countries is high. The issue is access to optimal treatment as there are not enough healthcare professional or facilities. In order to lower the high mortality rates, it is important to know why women present late. They conducted a qualitative study in Malaysia to find out and reasons include fatalism, belief in alternative therapies, poor decision-making, and financial problems.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 2 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
2 Views
Cancer-News 3 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 3 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
1 Views
Massachusetts General Hospital 3 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
1 Views
Cancer-News 3 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 3 days
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
2 Views
Cancer-News 3 days
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 3 days